Araştırma Makalesi
BibTex RIS Kaynak Göster

Bir üniversite hastanesinde yatan, digoksin ile tedavi edilen hastalarda omeprazol kullanımı: 2011-2015 yılları arasındaki veri analizi

Yıl 2018, , 1 - 8, 18.05.2018
https://doi.org/10.5505/deutfd.2018.07088

Öz

Giriş: Proton pompa inhibitörleri
(PPİ) Türkiye’de en çok reçetelenen ilaçların başında gelmektedir. Güvenli bir
ilaç olarak kabul edilmesi, bu kadar fazla reçetelenmesinde en büyük etkendir.
Ancak bu ilaç grubu içerisinde yer alan omeprazol birçok ilaç ile etkileşim
gösterebildiği için ilaç-ilaç etkileşimi açısından önem taşımaktadır. Bu
çalışmada digoksin kullanan olgulardan oluşan bir veri tabanında omeprazol
kullanım sıklığının, kullanım uygunluğunun ve hastaların kullandığı diğer
ilaçlar ile etkileşim olasılığının araştırılması planlanmıştır.



Gereç ve Yöntem: Üniversite hastanesi
elektronik hasta kayıtlarının incelendiği tanımlayıcı ve kesitsel türde bir
çalışmadır. Ocak 2011- Aralık 2015 tarihleri arasında kardiyoloji servisinde
yatan, oral yol digoksin ile tedavi edilen hastaların verileri tanımlayıcı
istatistik, ki-kare ve t-testi ile değerlendirildi. Omeprazol
kullanım endikasyon uygunluğu literatür kriterlerine göre belirlendi. Omeprazol
ile etkileşim olasılığı olan ilaç listesi Micromedex® İlaç Bilgi Kaynağından
elde edildi. Kanıt düzeyi çok iyi ve iyi düzeyde olan orta ve ciddi düzeyde
etkileşime neden olabilecek ilaçlar değerlendirmeye alındı.



Bulgu:
Toplam
1580 hastanın %69,4’ünde omeprazol kullanılmaktaydı. Bu hastaların yaş
ortalaması kullanılmayan gruba göre daha yüksekti (p<0,001). Omeprazol kullanım endikasyonu, hastaların %67,4’ünde
uygun bulundu. Omeprazol kullanım sıklığı 2014 yılında en azdı (%48,9). Ancak
endikasyon olmadan kullanım sıklığının bu yılda en fazla (%50,6) olduğu
görüldü. Seçilen örneklem nedeniyle omeprazol kullanan hastaların hepsi
digoksin ile tedavi edilmekte olan hastalardı. Omeprazol ile digoksinin
birlikte kullanımı için orta düzeyde etkileşim tanımlanmıştır. Orta düzeyde
etkileşime neden olabilecek diğer ilaçlar arasında en çok kullanılan (%41,5)
varfarin idi. Ciddi etkileşime girebilecek ilaçlar arasında ise en çok
kullanılan ilacın klopidogrel (%27) olduğu bulundu.



Sonuçlar: Digoksin kullanan kardiyoloji servis
hastalarında omeprazol kullanımı oldukça sıktır. Omeprazol kullanım endikasyonu
bu hasta grubunun çoğunda uygun olsa da ilaç-ilaç etkileşimi açısından dikkatli
olunması ve etkileşim riski daha düşük olan diğer PPİ’lerinin seçilmesi
önerilir.

Kaynakça

  • Uygun A. Uzun süre proton pompa inhibitörleri (PPI) kullanılacaksa, hangi PPI tercih edilmelidir? Nelere dikkat edilmelidir? Güncel Gastroenteroloji 2013;17:45-58.
  • Forte JG, Zhu L. Apical recycling of the gastric parietal cell H,K-ATPase. Annu Rev Physiol 2010;72:273-96.
  • Niklasson A, Bajora A, Bergendal L, M. Simren, H. Strid H. Bjornsson E. Overuse of acid suppressive therapy in hospitalized patients with pulmonary diseases. Respir Med 2003; 97:1143–1150.
  • Akram F, Huang Y, Lim V, Huggan PJ, Merchant RA. Proton pump inhibitors: Are we still prescribing them without valid indications? AMJ 2014;7:465–470.
  • Nardino RJ, Vender RJ, Herbert PN. Overuse of acid suppressive therapy in hospitalized patients. Am J Gastroenterol 2000;95:3118-22.
  • Nousheen, Tadvi NA, Shareef SM. Use of proton pump ınhibitors ın general practice: Is it rationale? Int J Med Res Health Sci 2014;3:37-42.
  • Ksiądzyna D, Szeląg A, Paradowski L. Overuse of proton pump inhibitors. Pol Arch Med Wewn 2015;125:289-98.
  • Gelal A. Yaşlılarda akılcı ilaç kullanımı. Turkiye Klinikleri J Pharmacol-Special Topics 2015;3:57-64.
  • Sutfin T, Balmer K, Boström H, et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989;11:176184.
  • Kiley CA, Cragin DJ, Roth BJ. Omeprazole associated digoxin toxicity. South Med J 2007;100:400402.
  • Oosterhuis B, Jonkman JH, Anderson T, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. B J Clin Pharmacol 1991;32:569572.
  • ACCF/ACG/AHA 2010 Expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol 2010;56:2051–66.
  • Parente F et al. Hospital use of acid‐suppressive medications and its fall‐out on prescribing in general practice: a 1‐month survey. Aliment Pharmacol Ther 2003;17:1503-1506.
  • Gürsoy MO, Yıldız M. Akut koroner sendromda tienopiridin ve proton pompa inhibitörü kullanımı. Koşuyolu Heart Journal 2016;19:37-39.
  • Johnson DA, Chilton R, Liker HR. Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling. Postgrad Med 2014;126:239-45.
  • Thomson Reuters Healthcare Web site. URL: www. micromedex. com/products/hcs. Erişim: Haziran 2017
  • Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali, WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004;57:1288-1294.
  • Villamanan E, Ruano M, Lara C, et al. Reasons for initiation of proton pump inhibitor therapy for hospitalised patients and its impact on outpatient prescription in primary care. Rev Esp Enferm Dig 2015;107:652-658. doi:10.17235/ reed.2015.3882/2015.
  • Nachnani JS, Bulchandani D, Moormeier J, Foxworth J. Patient and physician predictors of inappropriate acid-suppressive therapy (AST) use in hospitalized patients. J Hosp Med 2009;4:E10-E14. doi:10.1002/jhm.492.
  • De Rijdt T et al. Appropriateness of acid suppression therapy. Ann Pharmacother 2017;51:125-134.
  • Up ToDate 2017. URL: https://www.uptodate.com/contents/stress-ulcer-prophylaxis-in-the-intensive-care-unit Erişim tarihi: 28.06.2017
  • Oncu S, Gelal A, Aslan O, Ucku RS. Appropriateness of digoxin measurement in hospitalized patients. Biochem Med (Zagreb) 2018;28:010901. https://doi.org/ 10.11613/BM.2018.010901
  • Agewall S et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013;34:1708-1713.
  • US Food and Drug Administration 2009. URL: https://www.fda.gov/Drugs/DrugSafety/Postmarket
  • DrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm079520.htm Erişim tarihi: 03.07.2017.
  • Gilard M et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol 2008;51:256-260.
  • O'Donoghue ML, Braunwald E, Antman EM, Murphy SA et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. The Lancet 2009;374(9694): 989-997.
  • Craig DGN, Thimappa R, Anand V, Sebastian S. Inappropriate utilization of intravenous proton pump inhibitors in hospital practice—a prospective study of the extent of the problem and predictive factors. QJM 2010;103:327–35.
  • Ament PW, Dicola DB, James ME. Reducing adverse effects of proton pump inhibitors. Am Fam Physician 2012;86:66-70.
  • Atkins AM, Chandra Sekar M. Proton pump inhibitors: Their misuse, overuse and abuse. IOSR J Pharm 2013;3:25-9.

USE OF OMEPRAZOLE IN PATIENTS HOSPITALİZED IN A UNIVERSITY HOSPITAL AND TREATED WITH DIGOXİN: DATA ANALYSIS BETWEEN 2011-2015

Yıl 2018, , 1 - 8, 18.05.2018
https://doi.org/10.5505/deutfd.2018.07088

Öz

Objective: Proton pump inhibitors (PPI) are among the most frequently prescribed
drugs in Turkey. The main reason for the frequent prescription of this drug is
that it is regarded to be safe. However, omeprazole, which is in this group, is
important for drug-drug interactions as it can interact with many drugs. We
planned to investigate the frequency and appropriateness of omeprazole usage as
well as its probable interactions with other drugs in a data setting of digoxin
users. 

Material and
Method:
This is a descriptive and cross sectional
study in which electronic patient data in a university hospital were reviewed.
The data of the patients hospitalized between January
2011-December 2015 in the cardiology service and treated with oral digoxin were
evaluated in accordance with literature criteria. Data were analyzed using
descriptive statistics, chi-square
and t-test.
The drugs with potential
interaction risk with
omeprazole were selected from the Micromedex® Pharmaceutical Knowledge. Major and moderate interactions with excellent and good
evidence were evaluated.

Results: Omeprazole was used in 69.4% of the total of 1580
patients. Mean age of patients who used omeprazole was higher than those who
did not (p<0.001). In 67.4% of the
patients, omeprazole was used on appropriate indication. It was found that in 2014 the frequency of omeprazole use was lowest
(48.9%); whereas its use without indication was highest (50.6%).
All of
the patients using omeprazole were being treated with digoxin due to selected
sample of patients. Moderate interaction is defined for the combined use of
omeprazole and digoxin. Among the other drugs that may cause moderate
interactions, the most commonly used one was warfarin (41.5%). Among the drugs
that could cause major interaction, the most frequently used drug was
clopidogrel (27%).







Conclusion: Use of omeprazole was frequent in cardiology inpatients taking
digoxin.
Although omeprazole was used with appropriate
indication in the majority of this group, one should
beware of drug-drug interactions and prefer other PPIs with lower risk of
interaction. 

Kaynakça

  • Uygun A. Uzun süre proton pompa inhibitörleri (PPI) kullanılacaksa, hangi PPI tercih edilmelidir? Nelere dikkat edilmelidir? Güncel Gastroenteroloji 2013;17:45-58.
  • Forte JG, Zhu L. Apical recycling of the gastric parietal cell H,K-ATPase. Annu Rev Physiol 2010;72:273-96.
  • Niklasson A, Bajora A, Bergendal L, M. Simren, H. Strid H. Bjornsson E. Overuse of acid suppressive therapy in hospitalized patients with pulmonary diseases. Respir Med 2003; 97:1143–1150.
  • Akram F, Huang Y, Lim V, Huggan PJ, Merchant RA. Proton pump inhibitors: Are we still prescribing them without valid indications? AMJ 2014;7:465–470.
  • Nardino RJ, Vender RJ, Herbert PN. Overuse of acid suppressive therapy in hospitalized patients. Am J Gastroenterol 2000;95:3118-22.
  • Nousheen, Tadvi NA, Shareef SM. Use of proton pump ınhibitors ın general practice: Is it rationale? Int J Med Res Health Sci 2014;3:37-42.
  • Ksiądzyna D, Szeląg A, Paradowski L. Overuse of proton pump inhibitors. Pol Arch Med Wewn 2015;125:289-98.
  • Gelal A. Yaşlılarda akılcı ilaç kullanımı. Turkiye Klinikleri J Pharmacol-Special Topics 2015;3:57-64.
  • Sutfin T, Balmer K, Boström H, et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989;11:176184.
  • Kiley CA, Cragin DJ, Roth BJ. Omeprazole associated digoxin toxicity. South Med J 2007;100:400402.
  • Oosterhuis B, Jonkman JH, Anderson T, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. B J Clin Pharmacol 1991;32:569572.
  • ACCF/ACG/AHA 2010 Expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol 2010;56:2051–66.
  • Parente F et al. Hospital use of acid‐suppressive medications and its fall‐out on prescribing in general practice: a 1‐month survey. Aliment Pharmacol Ther 2003;17:1503-1506.
  • Gürsoy MO, Yıldız M. Akut koroner sendromda tienopiridin ve proton pompa inhibitörü kullanımı. Koşuyolu Heart Journal 2016;19:37-39.
  • Johnson DA, Chilton R, Liker HR. Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling. Postgrad Med 2014;126:239-45.
  • Thomson Reuters Healthcare Web site. URL: www. micromedex. com/products/hcs. Erişim: Haziran 2017
  • Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali, WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004;57:1288-1294.
  • Villamanan E, Ruano M, Lara C, et al. Reasons for initiation of proton pump inhibitor therapy for hospitalised patients and its impact on outpatient prescription in primary care. Rev Esp Enferm Dig 2015;107:652-658. doi:10.17235/ reed.2015.3882/2015.
  • Nachnani JS, Bulchandani D, Moormeier J, Foxworth J. Patient and physician predictors of inappropriate acid-suppressive therapy (AST) use in hospitalized patients. J Hosp Med 2009;4:E10-E14. doi:10.1002/jhm.492.
  • De Rijdt T et al. Appropriateness of acid suppression therapy. Ann Pharmacother 2017;51:125-134.
  • Up ToDate 2017. URL: https://www.uptodate.com/contents/stress-ulcer-prophylaxis-in-the-intensive-care-unit Erişim tarihi: 28.06.2017
  • Oncu S, Gelal A, Aslan O, Ucku RS. Appropriateness of digoxin measurement in hospitalized patients. Biochem Med (Zagreb) 2018;28:010901. https://doi.org/ 10.11613/BM.2018.010901
  • Agewall S et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013;34:1708-1713.
  • US Food and Drug Administration 2009. URL: https://www.fda.gov/Drugs/DrugSafety/Postmarket
  • DrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm079520.htm Erişim tarihi: 03.07.2017.
  • Gilard M et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol 2008;51:256-260.
  • O'Donoghue ML, Braunwald E, Antman EM, Murphy SA et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. The Lancet 2009;374(9694): 989-997.
  • Craig DGN, Thimappa R, Anand V, Sebastian S. Inappropriate utilization of intravenous proton pump inhibitors in hospital practice—a prospective study of the extent of the problem and predictive factors. QJM 2010;103:327–35.
  • Ament PW, Dicola DB, James ME. Reducing adverse effects of proton pump inhibitors. Am Fam Physician 2012;86:66-70.
  • Atkins AM, Chandra Sekar M. Proton pump inhibitors: Their misuse, overuse and abuse. IOSR J Pharm 2013;3:25-9.
Toplam 30 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Sağlık Kurumları Yönetimi
Bölüm Makaleler
Yazarlar

Şeyma Öncü Bu kişi benim

Ayşe Gelal Bu kişi benim 0000-0003-1910-7847

Özgür Aslan

Reyhan Uçku

Yayımlanma Tarihi 18 Mayıs 2018
Gönderilme Tarihi 13 Temmuz 2017
Yayımlandığı Sayı Yıl 2018

Kaynak Göster

Vancouver Öncü Ş, Gelal A, Aslan Ö, Uçku R. Bir üniversite hastanesinde yatan, digoksin ile tedavi edilen hastalarda omeprazol kullanımı: 2011-2015 yılları arasındaki veri analizi. DEU Tıp Derg. 2018;32(1):1-8.